scholarly journals Monte Carlo assessment of boron neutron capture therapy for the treatment of breast cancer

2005 ◽  
Vol 20 (1) ◽  
pp. 27-32 ◽  
Author(s):  
Daniel Mundy ◽  
Tatjana Jevremovic
Keyword(s):  
Breast Cancer ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Boron Concentration ◽  
Treatment Options ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Thermal Neutron Irradiation ◽  
Starting Point ◽  
Her 2

For a large number of women who are diagnosed with breast cancer every year the avail able treatment options are effective, though physically and mentally taxing. This work is a starting point of a study of the efficacy of boron neutron capture therapy as an alternative treatment for HER-2+ breast tumors. Using HER-2-specific monoclonal anti bodies coupled with a boron-rich oligomeric phosphate diester, it may be possible to deliver sufficient amounts of 10B to a tumor of the breast to al low for selective cell destruction via irradiation by thermal neutrons. A comprehensive computational model (MCNP) for thermal neutron irradiation of the breast is described, as well as the results of calculations made using this model, in order to determine the optimum boron concentration within the tumor for an effective boron neutron capture therapy treatment, as compared with traditional X-ray radiotherapy. The results indicate that a boron concentration of 50-60 mg per gram of tumor tissue is optimal when considering treatment times, dose distributions and skin sparing. How ever these results are based upon best-guess assumptions that must be experimentally verified.

scholarly journals Dosimetry of In Vivo Experiment for Lung Cancer Based on Boron Neutron Capture Therapy on Radial Piercing Beam Port Kartini Nuclear Reactor by MCNPX Simulation Method

2018 ◽  
Vol 35 (3) ◽  
pp. 213-216
Author(s):  
Atika Maysaroh ◽  
Kusminarto Kusminarto ◽  
Dwi Satya Palupi ◽  
Yohannes Sardjono
Keyword(s):  
Lung Cancer ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Boron Concentration ◽  
Gamma Ray ◽  
Neutron Capture Therapy ◽  
Thermal Neutrons ◽  
Boron Neutron Capture ◽  
Beam Port

Cancer is one of the leading causes of death globally, with lung cancer being among the most prevalent. Boron Neutron Capture Therapy (BNCT) is a cancer therapy method that uses the interaction between thermal neutrons and boron-10 which produces a decaying boron-11 particle and emits alpha, lithium 7 and gamma particles. A study was carried out to model an in vivo experiment of rat organisms that have lung cancer. Dimensions of a rat’s body were used in Konijnenberg research. Modeling lung cancer type, non-small cell lung cancer, was used in Monte Carlo N Particle-X. Lung cancer was modeled with a spherical geometry consisting of 3 dimensions: PTV, GTV, and CTV. In this case, the neutron source was from the radial piercing beam port of Kartini Reactor, Yogyakarta. The variation of boron concentration was 20, 25, 30, 35, 40, and 40 µg/g cancer. The output of the MCNP calculation was neutron scattering dose, gamma-ray dose and neutron flux from the reactor. A neutron flux was used to calculate the alpha proton and gamma-ray dose from the interaction of tissue material and thermal neutrons. The total dose was calculated from a four-dose component in BNCT. The results showed that the dose rate will increase when the boron concentration is higher, whereas irradiating time will decrease.

Cellular uptake evaluation of pentagamaboronon-0 (PGB-0) for boron neutron capture therapy (BNCT) against breast cancer cells

2019 ◽  
Vol 37 (6) ◽  
pp. 1292-1299
Author(s):  
Adam Hermawan ◽  
Ratna Asmah Susidarti ◽  
Ratna Dwi Ramadani ◽  
Lailatul Qodria ◽  
Rohmad Yudi Utomo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Cellular Uptake ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Breast Cancer Cells ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

Boron neutron capture therapy in non-SCC patients with intractable head and neck malignancies who have no other treatment options.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e17507-e17507
Author(s):  
Itsuro Kato ◽  
Yusei Fujita ◽  
Naofumi Yamamoto ◽  
Masatoshi Ohmae ◽  
Yoshinori Sakurai ◽  
...  
Keyword(s):  
Head And Neck ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Treatment Options ◽  
Neutron Capture Therapy ◽  
Head And Neck Malignancies ◽  
Boron Neutron Capture

scholarly journals Mechanistic Modeling of the Relative Biological Effectiveness of Boron Neutron Capture Therapy

Cells ◽  
2020 ◽  
Vol 9 (10) ◽  
pp. 2302
Author(s):  
Seth W. Streitmatter ◽  
Robert D. Stewart ◽  
Gregory Moffitt ◽  
Tatjana Jevremovic
Keyword(s):  
Cell Survival ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Relative Biological Effectiveness ◽  
Mechanistic Modeling ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Radiobiological Model ◽  
Biological Effectiveness ◽  
Her 2

Accurate dosimetry and determination of the biological effectiveness of boron neutron capture therapy (BNCT) is challenging because of the mix of different types and energies of radiation at the cellular and subcellular levels. In this paper, we present a computational, multiscale system of models to better assess the relative biological effectiveness (RBE) and compound biological effectiveness (CBE) of several neutron sources as applied to BNCT using boronophenylalanine (BPA) and a potential monoclonal antibody (mAb) that targets HER-2-positive cells with Trastuzumab. The multiscale model is tested against published in vitro and in vivo measurements of cell survival with and without boron. The combined dosimetric and radiobiological model includes an analytical formulation that accounts for the type of neutron source, the tissue- or cancer-specific dose–response characteristics, and the microdistribution of boron. Tests of the model against results from published experiments with and without boron show good agreement between modeled and experimentally determined cell survival for neutrons alone and in combination with boron. The system of models developed in this work is potentially useful as an aid for the optimization and individualization of BNCT for HER-2-positive cancers, as well as other cancers, that can be targeted with mAb or a conventional BPA compound.

scholarly journals Clinical trial design of Boron Neutron Capture Therapy on breast cancer using D-D coaxial compact neutron generator as neutron source and Monte Carlo N-Particle simulation method

2016 ◽  
Vol 1 (1) ◽  
pp. 34
Author(s):  
Rosenti Pasaribu ◽  
Kusminarto Kusminarto ◽  
Yohannes Sardjono
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Monte Carlo ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Generator ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
En Face ◽  
Compact Neutron Generator

<span>A clinical trial simulation of Boron Neutron Capture Therapy (BNCT) for breast cancer was conducted at National Nuclear Energy Agency Yogyakarta, Indonesia. This was motivated by high rate of breast cancer in the world, especially in Indonesia. BNCT is a type of therapy by nuclear reaction </span><sup>10</sup><span>B(n,α)</span><sup>7</sup><span>Li that produces kinetic energy totaling 2.79 MeV. High Linear Energy Transfer (LET) radiation of α-particle and recoil </span><sup>7</sup><span>Li would locally deposit their energy in a range of 5-9 μm, which corresponds to the human cell diameter. Fast neutron coming out of Compact Neutron Generator (CNG) was moderated using Fe and MgF</span><sub>2</sub><span> material. A collimator, along with breast cancer and the corresponding organ at risk were designed compatible to Monte Carlo N-Particle X (MCNPX). The radiation were simulated by the MCNPX software and the physical quantities were counted by tally MCNPX codes. The highest neutron thermal flux was found at a depth of 1.4 cm on fat tissue. En face and upward intersection radiation techniques were adopted for the breast cancer radiation. The average dose rate of radiation used on breast cancer was 1.72×10</span><sup>-5 </sup><span>Gy/s for the en face method and 8.98×10</span><sup>-6 </sup><span>Gy/s for the upward intersection method. Dose 50±3 Gy was given into cancer cell, (4.18±0.06) ×10</span><sup>-2</sup><span> Gy into heart and (8.16±0.06) ×10</span><sup>-2</sup><span>Gy into lung for 806.34 hours irradiation.</span>

scholarly journals CYTOPATHIC EFFECTS OF ACCELERATOR-BASED BORON NEUTRON CAPTURE THERAPY ON HUMAN GLIOBLASTOMA CELLS

2019 ◽  
Vol 18 (4) ◽  
pp. 34-42
Author(s):  
V. A. Byvaltsev ◽  
E. L. Zavjalov ◽  
V. V. Kanygin ◽  
A. I. Kasatova ◽  
A. I. Kichigin ◽  
...  
Keyword(s):  
Cell Line ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Boron Concentration ◽  
Neutron Capture Therapy ◽  
Neutron Sources ◽  
Cytopathic Effects ◽  
Boron Neutron Capture ◽  
Colony Forming Assay ◽  
U87 Cells

Boron neutron capture therapy (BNCT) is a targeted therapy based on a selective damage to cancer cells due to the interaction between boron-10 isotope and neutron. Reactor-based BNCT has been found to be effective in the treatment of high-grade gliomas. It is believed that compact accelerator-based neutron sources will ensure widespread adoption of the technique in clinical practice. New accelerator-based neutron sources are being actively developed all over the world. At the Institute of Nuclear Physics (Russia), the accelerator-based neutron source was developed for pre-clinical studies of BNCT.Purpose: to determine the cytopathic effects of accelerator-based BNCT on the human U87-glioblastoma cell line and to select a concentration of boron drugs that do not have a toxic effect on the cells before irradiation in vitro.Material and Methods. To assess the cytopathic effects (MTT test and colony-forming assay) of various concentrations of boron-containing drugs, U87 cells were incubated with boronophenylalanine (BPA) and sodium borocaptate (BSH) for 1, 2 and 10 days. The effect of BNCT on the U87 cell line was determined using colony-forming assay.Results. The MTT test showed a decrease in cell survival at a boron-10 isotope concentration of 160 μg/ml after 48 hours and 640 μg/ml after 24 hours of incubation for BPA. The cytopathic effects for sodium BSH appeared at a boron concentration of 80 µg / ml after 48 hours of incubation, and survival fraction of cells was reduced to 89 % compared to the control. According to the colonyforming assay, the cytotoxic effects of BSH and BPA at a boron concentration of 40 µg/ml in the medium were 79.6 and 84 %, respectively. The proportions of surviving cells were 18 ± 2 % and 13 ± 2 % after epithermal neutron irradiation in the presence of boronophenylalanine and in the presence of sodium borocaptate, respectively. Cell death without boron drugs occurred due to the neutron elastic scattering, nuclear reactions of thermal neutron capture by hydrogen and nitrogen, and accompanying gamma radiation.Conclusion. The study clearly showed a decrease in the proportion of surviving U87 cells after accelerator-based BNCT in the presence of 10B-enriched BSH and BPA. 

Sign in / Sign up

Export Citation Format

Share Document